started · updated
Biopharmaceutical firms 3S Bio and Sino Biopharmaceutical report growth and global expansion
Chinese biopharmaceutical companies 3S Bio and Sino Biopharmaceutical Limited have reported significant financial and strategic developments for the first half of 2026.
3S Bio reported interim revenue of RMB 4.53 billion, a 3.9% year-over-year increase, with net profit attributable to equity holders reaching RMB 1.15 billion. The company saw a 43% surge in overseas product sales and obtained marketing approvals in 23 countries. Additionally, 3S Bio continues to progress its partnership with Pfizer regarding the immuno-oncology therapeutic SSGJ-707, a deal with a potential value exceeding US$6 billion.
Sino Biopharmaceutical Limited has launched a new global brand, SBP Group, to facilitate its transition from a domestic leader to a global innovator. The company is focusing on product and business globalization through R&D and international partnerships. To date, the firm has completed four out-licensing transactions with multinational corporations, totaling over US$7 billion in potential value. A key 2026 transaction includes the exclusive licensing of rovadicitinib to Sanofi.
Entities
3S Bio · Pfizer · SBP Group · Sanofi · Sino Biopharmaceutical Limited
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 2 SOURCES] Sino Biopharmaceutical entered an exclusive licensing agreement with Sanofi for rovadicitinib in 2026. businessnewsweek.in · businessnewsthisweek.com
- [● 2 SOURCES] Sino Biopharmaceutical Limited launched a new global brand named SBP Group. businessnewsweek.in · businessnewsthisweek.com
- [● 2 SOURCES] Sino Biopharmaceutical has completed four out-licensing transactions with total potential value exceeding US$7 billion. businessnewsweek.in · businessnewsthisweek.com
- [○ 1 SOURCE] 3S Bio recorded revenue of RMB 4.53 billion for the first half of 2026. aijourn.com
- [○ 1 SOURCE] Net profit attributable to equity holders of 3S Bio reached RMB 1.15 billion in the first half of 2026. aijourn.com
- [○ 1 SOURCE] Overseas product sales for 3S Bio increased by 43% year-over-year. aijourn.com
- [○ 1 SOURCE] 3S Bio granted Pfizer global rights for SSGJ-707 in a deal with a potential value exceeding US$6 billion. aijourn.com